



T: 33.1.55.27.11.34
julien.leris@skadden.com

Education

Specialized Masters, HEC School of Management, 2017

Certification for the Profession of Attorney, Paris Bar School, 2016

Master's Degree, University of Montesquieu-Bordeaux IV, 2014

Bar Admissions

Paris

Julien Leris focuses his practice on private equity, corporate law and mergers and acquisitions.

Mr. Leris advises international and French clients on private equity and general corporate transactions, such as leveraged buyouts, build-ups, disposals and corporate restructurings. He has particular experience in the health care and renewable energy sectors.

Mr. Leris's experience includes counseling:

- **L'Occitane Groupe** and **Reinold Geiger**, the majority shareholder of L'Occitane International, in a take-private bid for L'Occitane International valuing the company at €6 billion
- **Grupo Bimbo**, the world's largest baking company, in its acquisition of Tunisia-based Moulin d'Or (GEPACO Group)
- **Energaz** in connection with several acquisitions of biogas plants in France and Germany and in the setup of joint ventures with other infrastructure funds
- **Ardian Private Equity** and **Merieux Equity Partners** in connection with:
 - the rollover of their co-investment stake in Humens (a spin-off of Seqens Group) and in Seqens Group
 - the sale of Humens to Leto
- **Galiena Capital** in several leveraged buyout transactions (acquisitions, disposals and build-ups), including the acquisition of Clufix Group, the sale of Spartner Group and the build-up by HAcare (a Galiena portfolio company) of Herdegen
- **Citi Ventures** in connection with its investment in Defacto, a French business-to-business fintech company
- **Financière LM**, a family office based in Belgium, in connection with the leveraged buyout of Délices de France
- **LBO France** in connection with the sale of Spine Innovations
- **several companies** in connection with their initial public offerings
- **Seven2** and **Crystal Group** in various external growth transactions
- **several groups in the health care sector** (ophthalmology and dental) during their consolidation phases and in build-up acquisitions